Health IT and Specialty Pharma Pivot Toward Remote Care and Clinical Milestones
Key Takeaways
- DocGo is successfully transitioning from large-scale government contracts to high-growth remote patient monitoring and mobile health services, while specialty firms like Kyntra Bio and Assertio are streamlining operations to focus on core clinical assets.
- These shifts reflect a broader industry trend toward sustainable, technology-driven care models and disciplined capital allocation.
Mentioned
Key Intelligence
Key Facts
- 1DocGo's non-migrant mobile health revenue grew by 47% year-over-year, driven by care gap closures and RPM.
- 2Kyntra Bio extended its cash runway into 2028 following the sale of FibroGen China to AstraZeneca.
- 3DocGo reported a 113% increase in healthcare-in-the-home visits and a 16% rise in remote patient monitoring.
- 4Assertio improved its quarterly gross margin to 75% despite a decrease in total product sales to $12.8 million.
- 5SteadyMD contributed over $8 million in revenue to DocGo in Q4, with gross margins rising to 37%.
- 6Kyntra Bio's FG3246 plus enzalutamide yielded a median radiographic progression-free survival of 10.1 months.
| Metric | |||
|---|---|---|---|
| Q4 Revenue | $74.9M | $12.8M | $1.3M |
| Cash Runway | N/A | N/A | Into 2028 |
| Key Growth Driver | Mobile Health/RPM | Sympazan/Rolvedon | FG3246 Oncology |
| Strategic Move | SteadyMD Integration | Restructuring/SG&A Cut | FibroGen China Sale |
Analysis
The fourth quarter of 2025 has emerged as a definitive transition period for several key players in the Healthcare and Health IT sectors. As the industry moves further away from the volatility of pandemic-era and emergency-response contracts, companies like DocGo and Kyntra Bio are aggressively realigning their business models to prioritize recurring revenue streams and high-value clinical pipelines. This strategic shift is characterized by a move toward 'Healthcare-in-the-home' and remote patient monitoring (RPM), which are increasingly seen as the primary drivers of long-term margin expansion in the Health IT space.
DocGo’s recent performance serves as a bellwether for this transition. While the company saw an explicit year-over-year revenue decline due to the wind-down of its migrant-related projects, its core non-migrant mobile health segment surged by 47%. This growth was fueled by a massive 113% increase in healthcare-in-the-home visits and a 16% rise in remote patient monitoring. The acquisition of SteadyMD has already begun to contribute significantly, adding over $8 million in quarterly revenue and improving gross margins to 37%. By raising its 2026 revenue guidance to a range of $290 million to $310 million, DocGo is signaling to investors that its pivot toward technology-enabled care gap closures and mobile phlebotomy is not just a defensive move, but a viable growth engine. The company’s focus on its 'Efficiency Innovation Portfolio,' which aims to deliver up to $24 million in annualized savings by 2027, further underscores a commitment to operational discipline that was often secondary during the rapid expansion of previous years.
The acquisition of SteadyMD has already begun to contribute significantly, adding over $8 million in quarterly revenue and improving gross margins to 37%.
In the specialty pharmaceutical and biotech arena, the theme of capital discipline is equally prevalent. Kyntra Bio’s sale of FibroGen China to AstraZeneca represents a critical strategic divestment, allowing the company to fully repay its senior secured term loan and extend its cash runway into 2028. This move provides the necessary financial cushion to advance its high-potential oncology assets, specifically the FG3246 and FG3180 programs for metastatic castration-resistant prostate cancer. The clinical data released—showing a median radiographic progression-free survival of 10.1 months in combination with enzalutamide—positions Kyntra as a serious contender in the prostate cancer market. The industry is closely watching for interim Phase II results expected in 2026, which will likely determine the company's next major valuation inflection point.
What to Watch
Assertio’s results highlight the complexities of managing specialty drug portfolios amidst generic competition and channel inventory fluctuations. Despite a sharp drop in total product sales for the quarter—largely due to timing issues with Rolvedon—the company managed to improve its gross margin to 75%. This was achieved through a favorable sales mix and aggressive restructuring that significantly reduced SG&A expenses. The resilience of products like Sympazan, which saw volume growth and a favorable payer mix, suggests that Assertio’s strategy of focusing on niche, high-margin therapies can sustain the business even as legacy products like Indocin face generic pressure. For analysts, the key takeaway is Assertio’s ability to exceed its full-year 2025 guidance despite the Q4 volatility, suggesting a stabilized operational foundation.
Looking ahead, the Healthcare IT sector is likely to see further consolidation as companies with strong cash positions, such as Kyntra and AEye (which also boasts a runway into 2028), look to acquire smaller innovators or invest in scaling their proprietary technologies. The success of DocGo’s RPM and mobile health initiatives will likely encourage competitors to accelerate their own digital health transitions. Investors should monitor the progress of these 'pivot' strategies, particularly the ability of these firms to maintain margin improvements while scaling their non-emergency service lines. The shift from episodic, contract-based revenue to longitudinal, patient-centered care models remains the most significant trend to watch in 2026.